The Stop Tuberculosis Partnership
The stop Tuberculosis (TB) partnership is a network of international organizations, countries, governmental and nongovernmental organizations, public and private sector donors, and individuals dedicated to the elimination of tuberculosis as a public health problem. The partnership is a loose coalition of partners working to elevate action on tuberculosis, one of the leading causes of death from infectious disease, on the global agenda. The stop TB partnership was formally established in 2001, as it became clear to the international community that the initial targets set for TB control in 1991.The specific objectives for which the partnership has been accountable have evolved somewhat since 2001, and have recently been stated most clearly in the global plan to stop TB, 2006-2015. Since the present Global Program Review (GPR) covers the period from the initiation of the program to the present, it has reviewed the achievements of the stop TB partnership against four objectives which have been synthesized from core partnership documents going back to 2001, namely: 1) to expand the Directly Observed Treatment Short-Course (DOTS) strategy so that all people have access to effective diagnosis and treatment; 2) to develop and scale-up effective responses to the emerging challenges of drug resistance and HIV-related TB; 3) to improve and expand tools available for TB diagnosis, treatment and prevention; and 4) to strengthen the overall global partnership to stop TB so that proven TB-control strategies are effectively applied.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
Washington, DC: World Bank ; 2009 |
| Reihe: |
Global Program Review - Vol. 4(1) |
|---|
| Sprache: |
Englisch en_US |
|---|
| Links: |
hdl.handle.net [kostenfrei] |
|---|
| ISBN: |
|---|
| Umfang: |
1 Online-Ressource |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1759280100 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1759280100 | ||
| 003 | DE-627 | ||
| 005 | 20220802234836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210601s2009 xx |||||o 00| ||und c | ||
| 020 | |a 9781602441255 |9 978-1-60244-125-5 | ||
| 035 | |a (DE-627)1759280100 | ||
| 035 | |a (DE-599)KEP063295849 | ||
| 035 | |a (OCoLC)1255455071 | ||
| 035 | |a (WBOKR)28058 | ||
| 035 | |a (EBP)063295849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a The Stop Tuberculosis Partnership |
| 264 | 1 | |a Washington, DC |b World Bank |c 2009 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a Global Program Review |v Vol. 4(1) | |
| 520 | |a The stop Tuberculosis (TB) partnership is a network of international organizations, countries, governmental and nongovernmental organizations, public and private sector donors, and individuals dedicated to the elimination of tuberculosis as a public health problem. The partnership is a loose coalition of partners working to elevate action on tuberculosis, one of the leading causes of death from infectious disease, on the global agenda. The stop TB partnership was formally established in 2001, as it became clear to the international community that the initial targets set for TB control in 1991.The specific objectives for which the partnership has been accountable have evolved somewhat since 2001, and have recently been stated most clearly in the global plan to stop TB, 2006-2015. Since the present Global Program Review (GPR) covers the period from the initiation of the program to the present, it has reviewed the achievements of the stop TB partnership against four objectives which have been synthesized from core partnership documents going back to 2001, namely: 1) to expand the Directly Observed Treatment Short-Course (DOTS) strategy so that all people have access to effective diagnosis and treatment; 2) to develop and scale-up effective responses to the emerging challenges of drug resistance and HIV-related TB; 3) to improve and expand tools available for TB diagnosis, treatment and prevention; and 4) to strengthen the overall global partnership to stop TB so that proven TB-control strategies are effectively applied | ||
| 540 | |f CC BY 3.0 IGO | ||
| 546 | |a English | ||
| 546 | |a en_US | ||
| 650 | 4 | |a ACQUIRED IMMUNODEFICIENCY SYNDROME | |
| 650 | 4 | |a ACQUISITION | |
| 650 | 4 | |a AIDS VACCINE | |
| 650 | 4 | |a ANTI-TB DRUGS | |
| 650 | 4 | |a ANTIGENS | |
| 650 | 4 | |a ANTIRETROVIRAL TREATMENT | |
| 650 | 4 | |a ARV | |
| 650 | 4 | |a BACTERIOLOGY | |
| 650 | 4 | |a BOARD MEETING | |
| 650 | 4 | |a BOARD MEMBER | |
| 650 | 4 | |a BURDEN OF DISEASE | |
| 650 | 4 | |a CAUSES OF DEATH | |
| 650 | 4 | |a CHARTER | |
| 650 | 4 | |a CHEMOTHERAPY | |
| 650 | 4 | |a CLINICAL TRIALS | |
| 650 | 4 | |a COLLECTIVE | |
| 650 | 4 | |a COLLECTIVE ACTION | |
| 650 | 4 | |a COMMUNICABLE DISEASES | |
| 650 | 4 | |a COMPANY | |
| 650 | 4 | |a CONFIRMED SPUTUM SMEAR | |
| 650 | 4 | |a CONSOLIDATION | |
| 650 | 4 | |a CONTROL PROGRAMS | |
| 650 | 4 | |a CORPORATE CONSTITUENCY | |
| 650 | 4 | |a CORPORATION | |
| 650 | 4 | |a CORPORATIONS | |
| 650 | 4 | |a DEVELOPMENT GRANT FACILITY | |
| 650 | 4 | |a DGF | |
| 650 | 4 | |a DIAGNOSIS | |
| 650 | 4 | |a DIAGNOSTICS | |
| 650 | 4 | |a DISABILITY | |
| 650 | 4 | |a DISEASE | |
| 650 | 4 | |a DISEASE CONTROL | |
| 650 | 4 | |a DNA | |
| 650 | 4 | |a DRUG COMPANIES | |
| 650 | 4 | |a DRUG RESISTANCE | |
| 650 | 4 | |a ENDEMIC COUNTRIES | |
| 650 | 4 | |a EPIDEMIC | |
| 650 | 4 | |a EPIDEMIOLOGICAL ASPECTS | |
| 650 | 4 | |a EPIDEMIOLOGY | |
| 650 | 4 | |a HEALTH CARE | |
| 650 | 4 | |a HEALTH SERVICES | |
| 650 | 4 | |a HEALTH STATUS | |
| 650 | 4 | |a HEALTH STATUS OF POOR | |
| 650 | 4 | |a HIB | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a HIV/AIDS | |
| 650 | 4 | |a IAVI | |
| 650 | 4 | |a IMMUNODEFICIENCY | |
| 650 | 4 | |a INDIVIDUALS | |
| 650 | 4 | |a INFECTION | |
| 650 | 4 | |a INFECTION CONTROL | |
| 650 | 4 | |a INFECTIOUS PATIENTS | |
| 650 | 4 | |a INTERESTED PARTIES | |
| 650 | 4 | |a INTERNATIONAL AIDS VACCINE INITIATIVE | |
| 650 | 4 | |a ISONIAZID | |
| 650 | 4 | |a LEPROSY | |
| 650 | 4 | |a LIMITED | |
| 650 | 4 | |a LUNG DISEASE | |
| 650 | 4 | |a LUNGS | |
| 650 | 4 | |a MALARIA | |
| 650 | 4 | |a MANAGERS | |
| 650 | 4 | |a MEMBER STATES | |
| 650 | 4 | |a MORTALITY | |
| 650 | 4 | |a NON-GOVERNMENTAL ORGANIZATION | |
| 650 | 4 | |a NON-GOVERNMENTAL ORGANIZATIONS | |
| 650 | 4 | |a PARTNERSHIP | |
| 650 | 4 | |a PARTNERSHIP FRAMEWORK | |
| 650 | 4 | |a PATIENTS | |
| 650 | 4 | |a PEDIATRIC TUBERCULOSIS | |
| 650 | 4 | |a PERSONS | |
| 650 | 4 | |a PREVALENCE | |
| 650 | 4 | |a PROPRIETARY | |
| 650 | 4 | |a PUBLIC HEALTH | |
| 650 | 4 | |a PULMONARY TUBERCULOSIS | |
| 650 | 4 | |a RESISTANT TUBERCULOSIS | |
| 650 | 4 | |a SECOND-LINE DRUGS | |
| 650 | 4 | |a SHORT COURSE CHEMOTHERAPY | |
| 650 | 4 | |a SMEAR POSITIVE | |
| 650 | 4 | |a SOCIETY | |
| 650 | 4 | |a SPUTUM SMEAR | |
| 650 | 4 | |a SPUTUM SMEAR MICROSCOPY | |
| 650 | 4 | |a STAKEHOLDER | |
| 650 | 4 | |a STAKEHOLDERS | |
| 650 | 4 | |a SYMPTOMATIC PATIENTS SELF-REPORTING | |
| 650 | 4 | |a SYMPTOMS | |
| 650 | 4 | |a TB | |
| 650 | 4 | |a TB CONTROL | |
| 650 | 4 | |a TREATMENT | |
| 650 | 4 | |a TREATMENT REGIMEN | |
| 650 | 4 | |a TROPICAL DISEASES | |
| 650 | 4 | |a TUBERCULOSIS | |
| 650 | 4 | |a TUBERCULOSIS CONTROL | |
| 650 | 4 | |a TUBERCULOSIS CONTROL STRATEGY | |
| 650 | 4 | |a TUBERCULOSIS EPIDEMIOLOGY | |
| 650 | 4 | |a TUBERCULOSIS PREVENTION | |
| 650 | 4 | |a UNION | |
| 650 | 4 | |a VACCINE | |
| 650 | 4 | |a VACCINE DEVELOPMENT | |
| 650 | 4 | |a VACCINE RESEARCH | |
| 650 | 4 | |a VACCINES | |
| 650 | 4 | |a VISION | |
| 710 | 2 | |a Independent Evaluation Group |e VerfasserIn |4 aut | |
| 856 | 4 | 0 | |u http://hdl.handle.net/10986/28058 |m X:WBOKR |x Resolving-System |z kostenfrei |
| 912 | |a ZDB-110-WBO | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a ISIL_DE-1a | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a ISIL_DE-206 | ||
| 912 | |a GBV_ILN_30 | ||
| 912 | |a ISIL_DE-104 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a ISIL_DE-705 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a ISIL_DE-Luen4 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a ISIL_DE-Ki95 | ||
| 912 | |a GBV_ILN_496 | ||
| 912 | |a ISIL_DE-Y9 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 951 | |a BO | ||
| 980 | |2 11 |1 01 |x 0001 |b 3992046311 |c 00 |f 5:LIZFREI |d --%%-- |e --%%-- |j --%%-- |h KERFADS WB |y k |z 21-10-21 | ||
| 980 | |2 26 |1 01 |x 0206 |b 3943134741 |h OLR-WBO |y znz |z 01-07-21 | ||
| 980 | |2 30 |1 01 |x 0104 |b 393559531X |h OLR-WBO |k World Bank Open Knowledge Repository |y z |z 07-06-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3939750751 |h OLR-WORLDBANK-OA |y xsn |z 19-06-21 | ||
| 980 | |2 60 |1 01 |x 0705 |b 4477160631 |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |k Nur für Angehörige der HSU: Volltextzugang von außerhalb des Campus mit Anmeldung über Shibboleth mit Ihrer Bibliothekskennung |y z |z 06-02-24 | ||
| 980 | |2 110 |1 01 |x 3110 |b 394008526X |h OLR-OA-Worldbank |k Open Access |k GBV-Worldbank-OA |y z |z 20-06-21 | ||
| 980 | |2 187 |1 01 |x 3520 |b 3939917109 |k GBV-Worldbank-OA |y z |z 20-06-21 | ||
| 980 | |2 496 |1 01 |x 3496 |b 4327144185 |c 00 |f --%%-- |d Online |e --%%-- |j --%%-- |h OLR-EBC |k Kostenfreier Zugriff / Open Access |y z |z 30-05-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 3936512361 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 09-06-21 | ||
| 981 | |2 26 |1 01 |x 0206 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 30 |1 01 |x 0104 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 60 |1 01 |x 0705 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 110 |1 01 |x 3110 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 187 |1 01 |x 3520 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 496 |1 01 |x 3496 |r http://hdl.handle.net/10986/28058 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r http://hdl.handle.net/10986/28058 | ||
| 983 | |2 496 |1 01 |x 3496 |8 00 |a Worldbank Open Knowledge Repository | ||
| 995 | |2 11 |1 01 |x 0001 |a KERFADS WB | ||
| 995 | |2 26 |1 01 |x 0206 |a OLR-WBO | ||
| 995 | |2 30 |1 01 |x 0104 |a OLR-WBO | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-WORLDBANK-OA | ||
| 995 | |2 110 |1 01 |x 3110 |a OLR-OA-Worldbank | ||
| 995 | |2 496 |1 01 |x 3496 |a OLR-EBC | ||